One study has demonstrated that activation of hepatic FXR improves the histological features of NASH by inducing the expression of fibroblast growth factor 21 (FGF21), a strong regulator of lipocalin, via the induction of upregulation of lipocalin expression (Cyphert et al., 2012), thereby improving insulin resistance and hepatic fat accumulation (Liu et al., 2020). This evidence concerns the gene INS and metabolic dysfunction-associated steatohepatitis.